Cervical carcinoma (squamous predominant + adeno) · line 2 · Tisotumab vedotin (recurrent/metastatic cervical cancer 2L+, innovaTV 204 / innovaTV 301)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-TISOTUMAB-VEDOTIN-CERVICAL-2L |
| ID | IND-CERVICAL-2L-TISOTUMAB-VEDOTIN |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-CERVICAL |
| Sources | SRC-ESMO-CERVICAL-2024 SRC-NCCN-CERVICAL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L+ for recurrent / metastatic cervical carcinoma post-platinum. NCCN- Cervical 2025 cat 1 / preferred; ESMO-Cervical 2024 recommended. FDA accelerated Sep 2021 (innovaTV 204) → full approval Apr 2024 (innovaTV 301 confirmatory). No biomarker prerequisite — TF broadly expressed on cervical carcinoma. Bibliographic record SRC-INNOVATV-204 (Coleman Lancet Oncol 2021, PMID 33845034) is available; SRC-INNOVATV-301 and SRC-FDA-TIVDAK remain source gaps. Clinical claim linkage, including UA access, requires review. UA access: named-patient pathway only.
Used By
Algorithms
ALGO-CERVICAL-METASTATIC-1L- ALGO-CERVICAL-METASTATIC-1L